Table 2 Univariate and multivariate Cox regression analyses of the 21-gene signature and OS in the validation set (early-stage LUAD)
Variables | Patients (N) | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | |||
GSE72094 | ||||||||
Age |  > 65/ ≤ 65 | 219/92 | 1.638 | 0.952–2.817 | 7.47E−02 | 1.807 | 1.042–3.135 | 3.52E−02 |
 Gender | Male/female | 141/170 | 1.449 | 0.917–2.289 | 1.12E−01 | 1.386 | 0.871–2.207 | 1.69E−01 |
 Stage | II/I | 65/246 | 2.137 | 1.313–3.479 | 2.24E−03 | 2.258 | 1.38–3.695 | 1.20E−03 |
 Smoking | Yes/no | 237/26 | 1.334 | 0.482–3.696 | 5.79E−01 |  |  |  |
 EGFR mutation | Yes/no | 35/276 | 0.092 | 0.013–0.659 | 1.76E−02 | 0.137 | 0.019–1.004 | 5.05E−02 |
 KRAS mutation | Yes/no | 105/206 | 1.701 | 1.075–2.691 | 2.33E−02 | 1.554 | 0.976–2.475 | 6.33E−02 |
 TP53 mutation | Yes/no | 77/234 | 1.461 | 0.893–2.392 | 1.31E−01 | 1.154 | 0.69–1.932 | 5.86E−01 |
 STK11 mutation | Yes/no | 48/263 | 0.799 | 0.41–1.559 | 5.11E−01 |  |  |  |
 Risk score | High/low | 89/222 | 2.952 | 1.857–4.695 | 4.79E−06 | 2.942 | 1.806–4.793 | 1.47E−05 |
TCGA-LUAD | ||||||||
 Age |  > 65/ ≤ 65 | 190/168 | 1.308 | 0.897–1.907 | 1.62E−01 | 1.513 | 1.018–2.249 | 4.05E−02 |
 Gender | Male/female | 168/199 | 1.069 | 0.739–1.546 | 7.25E−01 |  |  |  |
 Stage | II/I | 113/254 | 2.607 | 1.795–3.785 | 4.84E−07 | 2.186 | 1.444–3.309 | 2.19E−04 |
 T stage | T2/T1 | 201/141 | 1.423 | 0.942–2.147 | 9.35E−02 | 1.131 | 0.775–1.813 | 4.34E−01 |
 Smoking | Yes/no | 273/49 | 0.923 | 0.54–1.579 | 7.70E−01 |  |  |  |
 Risk score | High/low | 141/226 | 2.16 | 1.492–3.128 | 4.54E−05 | 1.909 | 1.279–2.849 | 1.55E−03 |